PMID-39780249 — EVOKE and EVOKE+ Design: Semaglutide in Early Alzheimer's Disease (Phase 3)

[DRAFT — authored 2026-04-19. Citation verified against PubMed 2026-04-19.]

Citation

Cummings JL, Atri A, Feldman HH, Hansson O, Hendrix S, Mummery CJ, Ismail Z, Waldemar G, Johannsen P, Liu-Seifert H, Stubbings V, Aggarwal A, Ye H, Chao S, Kivipelto M. Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Dement. 2025;21(1):e14303. doi: 10.1002/alz.14303. PMID: 39780249. PMCID: PMC11708093.

External URL: PubMed

Study Design

Design: Two parallel Phase 3 randomized, double-blind, placebo-controlled trials (evoke and evoke+)
Population: Adults aged 55-85 years with early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia) + biomarker-confirmed amyloid positivity
N: 3,808 total participants across both trials (NCT04777396 evoke + NCT04777409 evoke+)
Intervention: Once-daily oral semaglutide 14 mg (flexible dose) vs matching placebo
Treatment duration: 8-week titration + 104-week treatment + 52-week extension
Primary endpoint: Change in Clinical Dementia Rating – Sum of Boxes (CDR-SB)
Secondary endpoints: Cognitive (ADAS-Cog, MMSE), functional (ADCS-ADL), biomarkers (hsCRP, plasma tau, neurofilament light)

Key Points

Rationale: GLP-1R is expressed in hippocampus and cortex; preclinical data suggests neuroprotective effects via anti-inflammatory, anti-amyloid, and mitochondrial mechanisms. Observational data (e.g., T2D cohorts) suggested possible AD risk reduction with GLP-1 RA exposure.
Trial design rigor: Biomarker-confirmed AD (amyloid-PET or CSF) is a methodological strength; prior repurposing trials in AD have been limited by heterogeneous diagnosis.
Dose rationale: 14 mg oral semaglutide (Rybelsus) — the highest FDA-approved oral sem dose for T2D, chosen for CNS exposure and tolerability balance.
Companion to: PMID: 12789876 baseline characteristics paper published separately.

Clinical Relevance

EVOKE design paper established the methodological framework for the largest-to-date Phase 3 trials of a repurposed GLP-1 agent in Alzheimer's disease. The trials read out in 2025/2026 and the primary results (published as Johannsen CL et al. Lancet 2026) reported no significant CDR-SB benefit — the primary endpoint was not met.

Key teaching points:

Trial design is still considered methodologically sound — the null result is interpretable as a genuine null, not a design-driven artifact.
hsCRP reduction occurred with semaglutide (ETR 0.76 in EVOKE, 0.71 in EVOKE+) — biomarker improvements did not translate to clinical outcomes.
Biomarker-to-clinical gap is the important teaching point — AD biomarker effects do not guarantee clinical disease modification.
1-year extension discontinued based on primary-endpoint failure — Novo Nordisk will not pursue further AD development.

Linked Peptides

Semaglutide

Related Lessons

Lesson 5.2 — Semaglutide Deep Dive (Investigational / Cognitive indications — null finding framing)
Lesson 5.4 — Emerging indications

Related Studies

DOI-10-1016-S0140-6736-26-00459-9 – EVOKE Primary Results Johannsen Lancet 2026 — primary-results companion

PMID-39780249 – EVOKE EVOKE+ Design Oral Semaglutide Alzheimer